Nabriva Therapeutics (STU:NTY) Days Sales Outstanding : 267.16 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Days Sales Outstanding?

Nabriva Therapeutics's average Accounts Receivable for the three months ended in Jun. 2023 was €6.96 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was €2.38 Mil. Hence, Nabriva Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2023 was 267.16.

The historical rank and industry rank for Nabriva Therapeutics's Days Sales Outstanding or its related term are showing as below:

STU:NTY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.3 Med: 98.62 Max: 218.47
Current: 112.72

During the past 10 years, Nabriva Therapeutics's highest Days Sales Outstanding was 218.47. The lowest was 76.30. And the median was 98.62.

STU:NTY's Days Sales Outstanding is ranked worse than
70.55% of 893 companies
in the Biotechnology industry
Industry Median: 73.34 vs STU:NTY: 112.72

Nabriva Therapeutics's Days Sales Outstanding increased from Jun. 2022 (119.19) to Jun. 2023 (267.16).

Nabriva Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Nabriva Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Days Sales Outstanding Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

212.94

97.18

193.66

75.65

77.10

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Sales Outstanding	Get a 7-Day Free Trial															119.19	124.48	82.76	97.69	267.16

Competitive Comparison of Nabriva Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Nabriva Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Days Sales Outstanding falls into.

Nabriva Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Nabriva Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (8.863	+	5.362)	/	2 )	/	33.671	*	365
=	7.1125					/	33.671	*	365
=	77.10

Nabriva Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding (Q: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2023 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (9.816	+	4.097)	/	2 )	/	2.376	*	365 / 4
=	6.9565					/	2.376	*	365 / 4
=	267.16

Nabriva Therapeutics (STU:NTY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Nabriva Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (STU:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines